Relapse of AML patients to FLT3i treatment is the result of a long-term and stepwise process leading to resistance, whereby residual cancer cells initially survive and subsequently expand. Here, Joshi et al. use a multifaceted approach to characterize how microenvironment-driven early resistance to gilteritinib evolves into mutation-driven late resistance.

中文翻译：

---

AML 治疗耐药性的逐步演变

AML 患者对 FLT3i 治疗的复发是导致耐药性的长期和逐步过程的结果，残留的癌细胞最初存活并随后扩展。在这里，乔希等人。使用多方面的方法来表征微环境驱动的对 gilteritinib 的早期耐药性如何演变为突变驱动的晚期耐药性。